Delayed hypersensitivity to 5-fluorouracil associated with reduced dihydropyrimidine dehydrogenase (DPD) activity.
Duley
J A
JA
Purine Research Laboratory, UMDS Guy's Hospital, London, United Kingdom.
Nethersell
A B
AB
D000230:Adenocarcinoma / Q000188:drug therapy*; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D003404:Creatinine / Q000652:urine; D042943:Dihydrouracil Dehydrogenase (NADP); D004342:Drug Hypersensitivity / Q000097:blood / Q000201:enzymology* / Q000652:urine; D005472:Fluorouracil / Q000009:adverse effects*; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy*; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000097:blood / Q000201:enzymology* / Q000652:urine; D007962:Leukocytes / Q000201:enzymology; D008214:Lymphocytes / Q000201:enzymology* / Q000276:immunology; D008297:Male; D009963:Orotic Acid / Q000652:urine; D010088:Oxidoreductases / Q000097:blood*; D011560:Pseudouridine / Q000652:urine; D014498:Uracil / Q000652:urine
D000964:Antimetabolites, Antineoplastic; D011560:Pseudouridine; D014498:Uracil; D009963:Orotic Acid; D003404:Creatinine; D010088:Oxidoreductases; D042943:Dihydrouracil Dehydrogenase (NADP); D005472:Fluorouracil